If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Pharma co-organizer and diamond sponsor of RDD Europe 2019 conference in Estoril, Portugal

    Quick Contact
    • Aptar Pharma
    Aptar Pharma co-organizer and diamond sponsor of RDD Europe 2019 conference in Estoril, Portugal
    Europe, Iberia, Portugal, Health, Pharmaceuticals, Premium, Primary Packaging, Caps, Lids, Dispensing Closures, Sprays, Drug Delivery Devices, Active, Smart Packaging, Metal - Platinum, Stone, Stone - Diamond, Laboratory, Testing, Certification, National Certifications, FDA Approved

    Aptar Pharma, the leader in respiratory drug delivery systems, is proud to announce its co- organization and diamond sponsorship of the Respiratory Drug Delivery (RDD® ) Europe 2019 scientific conference, connecting pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal from May 7-10, 2019.

    One of the largest respiratory health conferences worldwide, RDD Europe 2019 is a premium, interactive three-day conference offering a prestigious program that includes a plenary lecture and seven plenary sessions hosted by industry experts - including a U.S. FDA speaker - who will share their perspectives and latest accomplishments in pulmonary and nasal drug delivery.

    This international symposium also offers delegates the latest insights into issues facing the global inhalation community, and numerous business networking opportunities.

    As part of their Diamond Sponsorship, Aptar Pharma will lead three interactive workshops dedicated to connected health. Entitled “The Future of Connected Medicines: Promise and Potential Pitfalls”, these sessions will take place on Wednesday, May 8 and will be presented by Sai Shankar Director, Business Development - Connected Devices at Aptar Pharma along with David Van Sickle, Co-founder and CEO at Propeller Health.

    Reaffirming their respiratory expertise, Aptar Pharma will also present two scientific posters during RDD Europe 2019, co-presented by Dr. Gerallt Williams, Director Scientific Affairs, Aptar Pharma:

    • “Human Factor studies for unit-dose nasal sprays – a case study”, co- presented by G. Williams, B. Grosjean, D. Chopard, P. Schwartz, J. Cabiddu

    • “Investigation of leachables from pMDIs containing HFA 152a”, co-presented by S. Sarrailh, A. Piquenot, O. Michelet, G. Williams.

    In addition to co-organizing the conference, Aptar Pharma will showcase their extensive portfolio of MDIs, DPIs and BAIs, including the growing range of connected devices, at an interactive Exhibit Table.

    Available as either add-on or fully integrated, Aptar’s c-devices can deliver improved patient health outcomes through better adherence. Also, discover the portfolio of active packaging solutions from Aptar CSP Technologies, now part of the Aptar family, which can help optimize your drug product’s packaging environment.

    As Platinum Sponsor, Aptar Pharma will be hosting the Gala Dinner at RDD Europe 2019, which will take place on Thursday May 9 at Sud Lisboa, located on the banks of the Tagus River in Lisbon. Gael Touya, President of Aptar Pharma, will be on hand to welcome guests to this much-anticipated event, which combines fine-cuisine, dancing and networking to cap off the conference.

    Register now at https://www.rddonline.com/rddeurope2019 for RDD Europe 2019 – a must-attend conference for companies involved in research, development, testing and marketing of medicines, as well as devices and services associated with pulmonary or nasal products.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 28 Mar 2019
    • Hits 856
    SR Packaging
    Webpackaging
    Conzept International